Impaired angiogenic response in the corneas of mice lacking osteopontin

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 2, 2010, Pages 790-794

  Fujita, Norihito ^a   Fujita, Shuko ^a   Okada, Yuka ^a   Fujita, Kyoko ^a   Kitano, Ai ^a   Yamanaka, Osamu ^a   Miyamoto, Takeshi ^a   Kon, Shigeyuki ^b   Uede, Toshimitsu ^b   Rittling, Susan R ^c   Denhardt, David T ^c   Saika, Shizuya ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPONTIN; SMAD3 PROTEIN; SYNAPTOPHYSIN; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN; CD31 ANTIGEN; MESSENGER RNA; SPP1 PROTEIN, MOUSE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CORNEA; CORNEA STROMA; FIBROBLAST CULTURE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WILD TYPE; ANIMAL; C57BL MOUSE; CELL CULTURE; CORNEA NEOVASCULARIZATION; CYTOLOGY; FIBROBLAST; METABOLISM; MOUSE MUTANT; NEWBORN; PERITONEUM MACROPHAGE; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; VASCULARIZATION;

ANIMALS; ANIMALS, NEWBORN; ANTIGENS, CD31; CELLS, CULTURED; CORNEA; CORNEAL NEOVASCULARIZATION; CORNEAL STROMA; FIBROBLASTS; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OSTEOPONTIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77449092459     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-3420     Document Type: Article

References (42)

1. Brodovsky SC, McCarty CA, Snibson G, et al. Management of alkali burns: an 11-year retrospective review. Ophthalmology. 2000;107: 1829-1835.
2. Meller D, Pires RT, Mack RJ, et al. Amniotic membrane transplantation for acute chemical or thermal burns. Ophthalmology. 2000; 107:980-989.
3. Saika S, Ikeda K, Yamanaka O, et al. Expression of Smad7 in mouse eyes accelerates healing of corneal tissue after exposure to alkali. Am J Pathol. 2005;166:1405-1418.
4. Saika S, Miyamoto T, Yamanaka O, et al. Therapeutic effect of topical administration of SN50, an inhibitor of nuclear factor-κB, in treatment of corneal alkali burns in mice. Am J Pathol. 2005;166: 1393-1403.
5. Saika S, Yamanaka O, Sumioka T, et al. Fibrotic disorders in the eye: targets of gene therapy. Prog Retin Eye Res. 2008;27:177-196.
6. Azar DT. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2006;104:264-302.
7. Papathanassiou M, Theodossiadis PG, Liarakos VS, Rouvas A, Giamarellos-Bourboulis EJ, Vergados IA. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol. 2008;145:424-431.
8. Saika S. TGFβ pathobiology in the eye. Lab Invest. 2006;86:106-115.
9. Fujita S, Saika S, Kao WW, et al. Endogenous TNFβ suppression of neovascularization in corneal stroma in mice. Invest Ophthalmol Vis Sci. 2007;48:3051-3055.
10. Francis ME, Uriel S, Brey EM. Endothelial cell-matrix interactions in neovascularization. Tissue Eng Part B Rev. 2008;14:19-32.
11. Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopontin): an early component of type I (cell-mediated) immunity. Science. 2000;287:860-864.
12. Bendeck MP, Irvin C, Reidy M, et al. Smooth muscle cell matrix metalloproteinase production is stimulated via alpha(v)beta(3) integrin. Arterioscler Thromb Vasc Biol. 2000;20:1467-1472.
13. Chabas D, Baranzini SE, Mitchell D, et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science. 2001;294:1731-1735.
14. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest. 2001;107:1055-1061.
15. Gadeau AP, Campan M, Millet D, Candresse T, Desgranges C. Osteopontin overexpression is associated with arterial smooth muscle cell proliferation in vitro. Arterioscler Thromb. 1993;13: 120-125.
16. Gravallese EM. Osteopontin: a bridge between bone and the immune system (published correction appears in J Clin Invest. 2003; 112:627). J Clin Invest. 2003;112:147-149.
17. O'Regan AW, Chupp GL, Lowry JA, et al. Osteopontin is associated with T cells in sarcoid granulomas and has T cell adhesive and cytokine-like properties in vitro. J Immunol. 1999;162:1024-1031.
18. O'Regan AW, Nau GJ, Chupp GL, Berman JS. Osteopontin (Eta-1) in cell-mediated immunity: teaching an old dog new tricks. Immunol Today. 2000;21:475-478.
19. Standal T, Borset M, Sundan A. Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol. 2004;26: 179-184.
20. Weber GF, Zawaideh S, Hikita S, et al. Phosphorylation-dependent interaction of osteopontin with its receptors regulates macrophage migration and activation. J Leukoc Biol. 2002;72:752-761.
21. Zhu B, Suzuki K, Goldberg HA, et al. Osteopontin modulates CD44-dependent chemotaxis of peritoneal macrophages through G-protein-coupled receptors: evidence of a role for an intracellular form of osteopontin. J Cell Physiol. 2004;198:155-167.
22. Ophascharoensuk V, Giachelli CM, Gordon K, et al. Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int. 1999;56:571-580.
23. O'Regan A. The role of osteopontin in lung disease. Cytokine Growth Factor Rev. 2003;14:479-488.
24. Takahashi F, Takahashi K, Okazaki T, et al. Role of osteopontin in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2001;24:264-271.
25. Liaw L, Birk D, Ballas C, et al. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest. 1998; 101:1468-1478.
26. Miyazaki K, Okada Y, Yamanaka O, et al. Corneal wound healing in an osteopontin-deficient mouse. Invest Ophthalmol Vis Sci. 2008; 49:1367-1375.
27. Alford AI, Hankenson KD. Matricellular proteins: extracellular modulators of bone development, remodeling, and regeneration. Bone. 2006;38:749-757.
28. Duvall CL, Taylor WR, Weiss D, Wojtowicz AM, Guldberg RE. Impaired angiogenesis, early callus formation, and late stage remodeling in fracture healing of osteopontin-deficient mice. J Bone Miner Res. 2007;4:67-72.
29. Bellahcène A, Castronovo V, Ogbureke KU, Fisher LW, Fedarko NS. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer. 2008;8:212-226.
30. Ramaiah SK, Rittling S. Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol Sci. 2008;103: 4-13.
31. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 2006;16:79-87.
32. Saika S, Ikeda K, Yamanaka O, et al. Loss of tumor necrosis factor a potentiates transforming growth factor b-mediated pathogenic tissue response during wound healing. Am J Pathol. 2006;168: 1848-1860.
33. Kitano A, Saika S, Yamanaka O, et al. Emodin suppression of ocular surface inflammatory reaction. Invest Ophthalmol Vis Sci. 2007; 48:5013-5022.
34. Hamada Y, Egusa H, Kaneda Y, et al. Synthetic osteopontin-derived peptide SVVYGLR can induce neovascularization in artificial bone marrow scaffold biomaterials. Dent Mater J. 2007;26:487-492.
35. Naldini A, Leali D, Pucci A, et al. Cutting edge: IL-1β mediates the proangiogenic activity of osteopontin-activated human monocytes. J Immunol. 2006;177:4267-4270.
36. Leali D, Dell'Era P, Stabile H, et al. Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis. J Immunol. 2003; 171:1085-1093.
37. Sato T, Nakai T, Tamura N, et al. Osteopontin/Eta-1 upregulated in Crohn's disease regulates the Th1 immune response. Gut. 2005; 54:1254-1262.
38. Xu G, Nie H, Li N, et al. Role of osteopontin in amplification and perpetuation of rheumatoid synovitis. J Clin Invest. 2005;115: 1060-1067.
39. Saika S, Miyamoto T, Ishida I, Ohnishi Y, Ooshima A. Osteopontin: a component of matrix in capsular opacification and subcapsular cataract. Invest Ophthalmol Vis Sci. 2003;44:1622-1628.
40. Saika S. Shirai K, Yamanaka O, et al. Loss of osteopontin perturbs the epithelial-mesenchymal transition in an injured mouse lens epithelium. Lab Invest. 2007;87:130-138.
41. Mori R, Shaw TJ, Martin P. Molecular mechanisms linking wound inflammation and fibrosis: knockdown of osteopontin leads to rapid repair and reduced scarring. J Exp Med. 2008;205:43-51.
42. Pflugfelder SC, Stern ME. Future directions in therapeutic interventions for conjunctival inflammatory disorders. Curr Opin Allergy Clin Immunol. 2007;7:450-453.